Latest Breaking News On - Asia outside - Page 2 : comparemela.com

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong First Drug Approval for Dayvigo in Asia Outside of Japan TOKYO, Mar 2, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for DAYVIGO in Asia outside of Japan. DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm. DAYVIGO binds to orexin receptors OX1R and OX2R and ac

United statesHong kongKostenloser wertpapierhandelAsia hong kongEisai hong kong co ltdEisai co ltdInstitute of medicineNational institute of public healthPublic relations departmentNational academiesInternational statistical classification of diseasesHealth problemsAmerica insomniaDrug approvalAsia outsideGeneric name